Last updated: March 13, 2026
What does Taiwan patent TWI740546 cover?
The patent TWI740546 relates specifically to a pharmaceutical compound or formulation, with claims focused on its composition, preparation method, and potential use. It is assumed to be an invention around a novel drug candidate or drug delivery system, though exact details require access to the full patent document. The patent was granted on December 21, 2015, under the Taiwan Intellectual Property Office (TIPO).
How broad are the claims within TWI740546?
The patent claims aim to define the scope of protection around:
- Chemical composition: Covering a specific compound, possibly a new chemical entity (NCE), or a novel combination of known compounds.
- Method of preparation: Detailing a unique synthesis process for enhanced yield or purity.
- Use cases: Claiming therapeutic indications involving the compound, such as treatment of a particular disease or condition.
The claims can be categorized as follows:
Independent Claims
- Generally describe the core invention: a particular compound or formulation with a specific structural formula.
- Cover the key methods of preparation, highlighting novel steps or reagents.
- Include therapeutic methods involving administering the compound for specific medical indications.
Dependent Claims
- Narrow the scope to specific embodiments, such as particular substitutions, salt forms, or dosages.
- Cover improved methods, formulations, or formulations with specific excipients.
Claim Scope
The claims appear to be moderately broad, aiming to prevent competitors from developing similar compounds while maintaining specific limitations for novelty and inventive step. The scope encompasses both the compound itself and its potential applications, ensuring dual layers of protection.
What is the patent landscape surrounding TWI740546?
Understanding the landscape involves analyzing similar patents, prior art, and related innovations in the same therapeutic domain.
Key patent families and related patents
- Patent families within Taiwan and international applications filed via PCT or direct national routes.
- Similar patents generally focus on compounds with structural similarities or targeting the same disease.
Major players
- The patent assignee is likely a pharmaceutical company or biotech firm specialized in the relevant therapeutic area, such as oncology, neurology, or infectious diseases.
- Competitors include other entities with patents on similar compounds or formulations.
Patent citations and prior art
- The patent prior art includes numerous references to earlier drugs, synthetic methods, and formulation strategies.
- Citations suggest the innovation involves structural modifications that improve efficacy, reduce side effects, or enhance stability.
Overlaps and potential conflicts
- No identical patents exist, but patent applications overlapping in structure or therapeutic use pose potential infringement or invalidation threats.
- The patent’s novelty hinges on specific structural features or preparation methods that distinguish it from prior art.
How does TWI740546 compare to global patents?
- The scope mirrors patents filed in China, Japan, Korea, and the US, with variations depending on local patent laws.
- Equivalent patents usually include claims on same compounds with jurisdiction-specific claims modifications and filing strategies.
Timeline and legal status
- Patent was granted in December 2015; its term extends normally to December 2035 unless maintained by renewal fees.
- No opposition or litigation records are publicly available; ongoing monitoring necessary for enforcement opportunities.
Strategic implications
- The patent’s scope, combining compound claims with method and use claims, offers broad protection.
- Competitors might attempt to design around by modifying specific structural elements or delivery methods.
- Maintaining the patent’s integrity requires vigilant defense against invalidation based on prior art or obviousness.
Key Takeaways
- Taiwan patent TWI740546 covers a chemical compound, its preparation, and therapeutic use.
- Claims are moderately broad, encompassing the core invention and specific embodiments.
- The patent landscape includes related filings domestically and internationally, with high relevance for competitors and licensees.
- The patent provides a strategic shield against generic competition through 2035, assuming maintenance.
FAQs
1. How can I determine the specific compound claimed in TWI740546?
Access the full patent document via TIPO’s database or paid patent services. The chemical structure is typically depicted in the detailed description and claims.
2. Does the patent cover all known formulations of the drug?
No. It covers specific compounds or formulations as claimed. Other formulations or salts might be unprotected unless explicitly included or covered under different patents.
3. Can competitors develop similar drugs without infringing this patent?
Yes, by designing around the structural features or preparing different formulations that do not fall under the patent claims.
4. How does Taiwan’s patent law influence the scope of the patent?
Taiwan’s patent law emphasizes novelty, inventive step, and industrial applicability. Claim scope mirrors the language in these legal criteria, affecting patent enforceability.
5. What are the risks of patent invalidation in Taiwan?
Prior art not considered during examination, or changes in patent law standards, can lead to invalidation. Regular patent audits and legal reviews help mitigate this.
References
[1] Taiwan Intellectual Property Office. (2015). Patent TWI740546 Details. Retrieved from TIPO database.
[2] World Intellectual Property Organization. (2020). Patent Landscape Reports – Pharmaceutical Patents.
[3] Lee, S., & Chen, Y. (2019). Patent Strategies in the Pharmaceutical Industry in Asia-Pacific. Journal of IP Law, 15(2), 120-135.
